From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy

被引：55

作者：

Georgakis, Georgios V. ^{[1
]}

Younes, Anas ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2006年 / 6卷 / 01期

关键词：

AP23573; apoptosis; CCI-779; cell cycle; lymphoma; RAD001;

D O I：

10.1586/14737140.6.1.131

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

One of the most prominent pathways explored in the area of targeted therapy is the PI3K/Akt/mTOR pathway, which plays a central role in cell survival and proliferation. Deregulation of this pathway has been implicated in the promotion of cancer cell growth and survival. Inhibition of several steps of this pathway has been shown to confer favorable antitumor activity in a variety of cancer types. This article provides a brief analysis of the PI3K/Akt/mTOR pathway, its importance in tumor pathogenesis and the current status of preclinical and clinical studies targeting signaling components of this pathway.

引用

页码：131 / 140

页数：10

共 87 条

[1] Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha [J].

Alessi, DR ;

James, SR ;

Downes, CP ;

Holmes, AB ;

Gaffney, PRJ ;

Reese, CB ;

Cohen, P .

CURRENT BIOLOGY, 1997, 7 (04) :261-269

[2] 3 Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro [J].

Alessi, DR ;

Kozlowski, MT ;

Weng, QP ;

Morrice, N ;

Avruch, J .

CURRENT BIOLOGY, 1998, 8 (02) :69-81

[3] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[4] Negative regulation of mixed lineage kinase 3 by protein kinase B/AKT leads to cell survival [J].

Barthwal, MK ;

Sathyanarayana, P ;

Kundu, CN ;

Rana, B ;

Pradeep, A ;

Sharma, C ;

Woodgett, JR ;

Rana, A .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (06) :3897-3902

[5] The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation [J].

Beuvink, I ;

Boulay, A ;

Fumagalli, S ;

Zilbermann, F ;

Ruetz, S ;

O'Reilly, T ;

Natt, F ;

Hall, J ;

Lane, HA ;

Thomas, G .

CELL, 2005, 120 (06) :747-759

[6] A human protein kinase Bγ with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain [J].

Brodbeck, D ;

Cron, P ;

Hemmings, BA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (14) :9133-9136

[7] A MAMMALIAN PROTEIN TARGETED BY G1-ARRESTING RAPAMYCIN-RECEPTOR COMPLEX [J].

BROWN, EJ ;

ALBERS, MW ;

SHIN, TB ;

ICHIKAWA, K ;

KEITH, CT ;

LANE, WS ;

SCHREIBER, SL .

NATURE, 1994, 369 (6483) :756-758

[8] Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor [J].

Brunet, A ;

Bonni, A ;

Zigmond, MJ ;

Lin, MZ ;

Juo, P ;

Hu, LS ;

Anderson, MJ ;

Arden, KC ;

Blenis, J ;

Greenberg, ME .

CELL, 1999, 96 (06) :857-868

[9] Regulation of cell death protease caspase-9 by phosphorylation [J].

Cardone, MH ;

Roy, N ;

Stennicke, HR ;

Salvesen, GS ;

Franke, TF ;

Stanbridge, E ;

Frisch, S ;

Reed, JC .

SCIENCE, 1998, 282 (5392) :1318-1321

[10] Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer [J].

Chan, S .

BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1420-1424

← 1 2 3 4 5 6 7 8 9 →